Preventive Haegarda Reduces Swelling Attacks in Pediatric HAE Patients, Trial Data Shows
Preventive treatment with Haegarda, an under-the-skin C1-INH replacement medication by CSL Behring, significantly lowers the number of swelling episodes experienced by children and adolescents with hereditary angioedema (HAE), an analysis of the COMPACT trial’s open-label extension study found. The treatment caused a 97% reduction in HAE…